ASLAN Pharmaceuticals to Present Additional Data From Interim Analysis of TREK-DX Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients During Virtual KOL Event

Press/Media

Period	7 May 2024

Media coverage

Title	ASLAN Pharmaceuticals to Present Additional Data From Interim Analysis of TREK-DX Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients During Virtual KOL Event
Media name/outlet	BioSpace
Country/Territory	United States
Date	7/05/24
URL	ct.moreover.com/?a=53760437366&p=1gw&v=1&x=sifYY_SOyObQYQMIrgd7NA
Persons	Peter Lio